Investments in and Advances to Unconsolidated Joint Ventures (Tables)

6 Months Ended

Jun. 30, 2018

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Equity Method Investments

The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands):

			Carrying Amount
			June 30,		December 31,
Entity(1)	Ownership%		2018		2017
CCRC JV		49	$	383,274	$	400,241
RIDEA II(2)		40	—		259,651
U.K. JV		49	104,955		—
Life Science JVs(3)		50 - 63	64,814		65,581
MBK JV		50	36,781		38,005
Development JVs(4)		50 - 90	25,008		23,365
Medical Office JVs(5)		20 - 67	12,428		12,488
K&Y JVs(6)		80	1,336		1,283
Advances to unconsolidated joint ventures, net			11		226
			$	628,607	$	800,840

_______________________________________

(1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.

(2) Effective January 1, 2018, the Company increased its carrying value in RIDEA II as a net adjustment to retained earnings under its elected transition approach in accordance with the adoption of ASU 2017-05 (see Note 2). In June 2018, the Company sold its equity method investment in RIDEA II (see Note 4).

(3) Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%); and (iii) LASDK, LP (63%).

(4) Includes four unconsolidated SHOP development partnerships (and the Company’s ownership percentage): (i) Vintage Park Development JV (85%); (ii) Waldwick JV (85%); (iii) Otay Ranch JV (90%); and (iv) MBK Development JV (50%).

(5) Includes three unconsolidated medical office partnerships (and the Company’s ownership percentage): HCP Ventures IV, LLC (20%); HCP Ventures III, LLC (30%); and Suburban Properties, LLC (67%).

(6) Includes three unconsolidated JVs.